Sprint Bioscience deal

Sprint granted an undisclosed U.S. company worldwide rights to develop and commercialize Sprint’s phosphatidylinositol-5-phosphate 4-kinase type II alpha (PIP4K2A) inhibitor program targeting tumor m...